A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Avelumab (Primary) ; Tomivosertib (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Effector Therapeutics
- 09 Jul 2018 Planned End Date changed from 1 Nov 2018 to 1 Mar 2019.
- 09 Jul 2018 Planned primary completion date changed from 1 May 2018 to 1 Mar 2019.
- 14 May 2018 According to an Effector Therapeutics media release, the company has dosed the first patient in the randomized portion of this trial.